AI is Changing the Paradigm | Clinical Trials for Cancer

Massive Bio's CEO and Co-Founder, Selin Kurnaz, Phd, discusses how artificial intelligence is changing the paradigm in oncology clinical trials at the Ai4 2nd Annual Artificial Intelligence Healthcare Conference in New York.

Massive Bio provides free cancer clinical trial matching services to cancer patients through the development of an AI-powered platform that matches a patient's tumor type and biomarkers within a database of over 30,000 active clinical trials throughout the world. Massive Bio's mission is to improve cancer patient access to clinical trials regardless of where they live or the ability to pay.

For more Oncology Information, you can visit:

Find more sources for oncology and join our newsletter for e-mailing:

You can subscribe to our channel to follow all oncology contents.

#ceo #healthtech #leadership #cancerresearch #clinicaltrials #ArtificialIntelligence #MassiveBio

[MassiveBio]

You can subscribe to our channel to follow all oncology contents.

At Massive Bio, we believe all cancer patients deserve equal access to leading edge therapies and new-emerging clinical trials, regardless of where they live or their ability to pay.